ATE394115T1 - Diagnose der alzheimer-krankheit auf basis von mitogenaktivierter proteinkinase-phosphorylierung - Google Patents
Diagnose der alzheimer-krankheit auf basis von mitogenaktivierter proteinkinase-phosphorylierungInfo
- Publication number
- ATE394115T1 ATE394115T1 AT02723236T AT02723236T ATE394115T1 AT E394115 T1 ATE394115 T1 AT E394115T1 AT 02723236 T AT02723236 T AT 02723236T AT 02723236 T AT02723236 T AT 02723236T AT E394115 T1 ATE394115 T1 AT E394115T1
- Authority
- AT
- Austria
- Prior art keywords
- alzheimer
- mitogen
- diagnosis
- protein kinase
- activated protein
- Prior art date
Links
- 230000026731 phosphorylation Effects 0.000 title abstract 3
- 238000006366 phosphorylation reaction Methods 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 102000043136 MAP kinase family Human genes 0.000 title 1
- 108091054455 MAP kinase family Proteins 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 239000012190 activator Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 101800004538 Bradykinin Proteins 0.000 abstract 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 abstract 1
- 102100035792 Kininogen-1 Human genes 0.000 abstract 1
- 101150018665 MAPK3 gene Proteins 0.000 abstract 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27141601P | 2001-02-27 | 2001-02-27 | |
| US32950501P | 2001-10-17 | 2001-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE394115T1 true ATE394115T1 (de) | 2008-05-15 |
Family
ID=26954877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02723236T ATE394115T1 (de) | 2001-02-27 | 2002-02-27 | Diagnose der alzheimer-krankheit auf basis von mitogenaktivierter proteinkinase-phosphorylierung |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7682807B2 (de) |
| EP (1) | EP1385531B1 (de) |
| JP (3) | JP4246495B2 (de) |
| KR (2) | KR100941597B1 (de) |
| CN (1) | CN1549721B (de) |
| AT (1) | ATE394115T1 (de) |
| AU (1) | AU2002254029A1 (de) |
| DE (2) | DE08002964T1 (de) |
| ES (2) | ES2305234T3 (de) |
| WO (1) | WO2002067764A2 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE394115T1 (de) * | 2001-02-27 | 2008-05-15 | Brni Neurosciences Inst | Diagnose der alzheimer-krankheit auf basis von mitogenaktivierter proteinkinase-phosphorylierung |
| US20050054017A1 (en) | 2002-11-27 | 2005-03-10 | Sugen, Inc. | Phosphospecific PAK antibodies and diagnostic kits |
| US20060040338A1 (en) * | 2004-08-18 | 2006-02-23 | Odyssey Thera, Inc. | Pharmacological profiling of drugs with cell-based assays |
| US20060094059A1 (en) * | 2004-09-22 | 2006-05-04 | Odyssey Thera, Inc. | Methods for identifying new drug leads and new therapeutic uses for known drugs |
| CA2582270A1 (en) * | 2004-11-15 | 2006-05-26 | Blanchette Rockefeller Neurosciences Institute | Abnormalities of phosphatase 2a (pp2a) for diagnosis and treatment of alzheimer's disease |
| AR053272A1 (es) * | 2005-05-11 | 2007-04-25 | Hoffmann La Roche | Determinacion de responsivos a la quimioterapia |
| WO2007044094A1 (en) * | 2005-10-11 | 2007-04-19 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb) |
| WO2007043998A1 (en) * | 2005-10-11 | 2007-04-19 | Blanchette Rockefeller Neurosciences Institute | Alzheimer’s disease-specific alterations of the erk1/erk2 phosphorylation ratio |
| US20080221042A1 (en) * | 2005-10-11 | 2008-09-11 | Tapan Kumar Khan | Alzheimer's disease-specific alterations of the ERK1/ERK2 Phosphorylation ratio-Alzheimer's disease-specific molecular biomarkers (ADSMB) |
| US20090029873A1 (en) * | 2005-10-11 | 2009-01-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb) |
| US7595167B2 (en) | 2005-10-11 | 2009-09-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio |
| EP1934618B1 (de) * | 2005-10-11 | 2009-05-13 | Blanchette Rockefeller Neurosciences Institute | Morbus alzheimer-spezifische veränderungen des erk1/erk2-phosphorylierungsverhältnisses - morbus alzheimer-spezifische molekulare biomarker (adsmb) |
| GB0708075D0 (en) * | 2007-04-26 | 2007-06-06 | Univ Nottingham | Nethods |
| EP3586839A1 (de) | 2008-07-28 | 2020-01-01 | Blanchette Rockefeller Neurosciences, Institute | Pkc-aktivierende verbindungen zur behandlung von neurodegenerativen erkrankungen |
| JP2011529344A (ja) * | 2008-07-28 | 2011-12-08 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | アルツハイマー病の刺激誘発ゲノムプロフィールマーカー |
| CN102224256A (zh) * | 2008-08-27 | 2011-10-19 | H.隆德贝克有限公司 | 用于测量生物标记概况的系统和方法 |
| BR112012007557A2 (pt) | 2009-10-02 | 2017-05-02 | Blanchette Rockefeller Neurosciences Inst | alterações anormais de processamento de isozimas de pkc em células periféricas da doença de alzheimer |
| EP2483684B1 (de) * | 2009-10-02 | 2018-04-18 | Blanchette Rockefeller Neurosciences, Institute | Fibroblast wachstumsmuster zur diagnose der alzheimer-krankheit |
| US9163032B2 (en) | 2011-11-13 | 2015-10-20 | Blanchette Rockefeller Neurosciences Insitute | Esters of DCPLA and methods of treatment using the same |
| ES2495266B8 (es) | 2013-02-13 | 2015-11-12 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer |
| JP6584322B2 (ja) * | 2013-12-27 | 2019-10-02 | 国立大学法人 東京医科歯科大学 | アルツハイマー病及び前頭側頭葉変性症の診断方法、診断薬、治療薬、及びこれら薬剤のスクリーニング方法 |
| ES2598885B1 (es) * | 2015-06-30 | 2017-10-09 | Consejo Superior De Investigaciones Científicas | Método para determinar el riesgo de desarrollar la enfermedad de Alzheimer |
| CN106442963B (zh) * | 2016-09-14 | 2018-09-14 | 江苏康缘药业股份有限公司 | 一种检测引起类过敏反应的物质的方法及其试剂盒 |
| WO2018183703A1 (en) | 2017-03-31 | 2018-10-04 | NeuroDiagnostics LLC | Lymphocyte-based morphometric test for alzheimer's disease |
| AU2018300159A1 (en) | 2017-07-12 | 2020-02-06 | Texas Tech University System | MicroRNA-455-3p as a peripheral biomarker for Alzheimer's disease |
| EP3658172A4 (de) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | Behandlung von krebs durch blockierung der interaktion von tim-3 und seinem liganden |
| CA3090356A1 (en) * | 2018-03-11 | 2019-09-19 | Koorosh Shahpasand | Conformation-independent antibodies against neurotoxic tau proteins |
| CN113711036B (zh) | 2019-01-30 | 2025-03-18 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| WO2020176573A1 (en) * | 2019-02-26 | 2020-09-03 | NeuroDiagnostics LLC | Methods for diagnosing alzheimer's disease based on cell growth rate, size and protein amount |
| KR102295114B1 (ko) | 2019-12-30 | 2021-08-27 | 경상국립대학교산학협력단 | 알츠하이머 병기 예측용 조성물 및 상기 조성물을 이용한 예측 키트 |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6080784A (en) | 1986-06-11 | 2000-06-27 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators N |
| US5242932A (en) | 1991-12-17 | 1993-09-07 | The Rockefeller University | Treatment of amyloidosis associated with alzheimer disease |
| US5385915A (en) | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
| WO1993011231A1 (en) | 1991-12-06 | 1993-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Tools for the diagnosis and treatment of alzheimer's disease |
| US6107050A (en) | 1993-05-03 | 2000-08-22 | The United States Of America As Represented By The Department Of Health And Human Services | Diagnostic test for alzheimers disease |
| US5976816A (en) | 1993-05-03 | 1999-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Cell tests for alzheimer's disease |
| US20030108956A1 (en) | 1993-05-03 | 2003-06-12 | Alkon Daniel L. | Cell tests for Alzheimer's disease |
| US7625697B2 (en) | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
| HUT77081A (hu) * | 1994-10-28 | 1998-03-02 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Protein kináz NPK-110 |
| US6001580A (en) * | 1995-03-28 | 1999-12-14 | Takeda Chemical Industries, Inc. | Method for assaying ERK2 map kinase |
| CN1189816A (zh) * | 1995-05-01 | 1998-08-05 | 匹兹堡大学 | 用于阿尔茨海默氏病死亡前诊断以及体内成像和防止淀粉样蛋白沉积的偶氮化合物 |
| WO1997032020A2 (en) | 1996-02-29 | 1997-09-04 | Mount Sinai Hospital Corporation | Shc proteins |
| JPH1090263A (ja) | 1996-07-25 | 1998-04-10 | Mclean Hospital Corp:The | アルツハイマー病の診断のためのｅｒｋ−１およびｅｒｋ−２の利用 |
| GB9803399D0 (en) * | 1998-02-19 | 1998-04-15 | Imp Cancer Res Tech | Protein kinase c |
| WO2000020867A1 (en) | 1998-10-01 | 2000-04-13 | Alexey Vladimirovich Titievsky | A novel ret-independent signaling pathway for gdnf |
| AU5150300A (en) | 1999-05-19 | 2000-12-05 | Mitokor | Differential gene expression in specific regions of the brain in neurodegenerative diseases |
| WO2001027624A2 (en) | 1999-10-08 | 2001-04-19 | Superarray, Inc. | Compositions and methods for detecting protein modification and enzymatic activity |
| US20030165481A1 (en) | 2000-02-24 | 2003-09-04 | Hersh Louis B. | Amyloid peptide inactivating enzyme to treat Alzheimer's disease |
| JP2003527604A (ja) | 2000-03-10 | 2003-09-16 | ワシントン・ユニバーシティ | 個々の細胞の標識方法 |
| EP1315971A2 (de) | 2000-07-31 | 2003-06-04 | The Regents of The University of California | Modell für alzheimer und neurodegenerative krankheiten |
| AUPR215700A0 (en) | 2000-12-19 | 2001-01-25 | Fujisawa Pharmaceutical Co., Ltd. | Carboxylic acid compound having cyclopropane ring |
| CA2437497A1 (en) | 2001-02-06 | 2002-08-15 | Incyte Genomics, Inc. | Lipid-associated molecules |
| ATE394115T1 (de) | 2001-02-27 | 2008-05-15 | Brni Neurosciences Inst | Diagnose der alzheimer-krankheit auf basis von mitogenaktivierter proteinkinase-phosphorylierung |
| US20040014678A1 (en) | 2001-08-08 | 2004-01-22 | Antonella Favit | Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytoc pathway |
| WO2004083241A2 (en) | 2003-03-19 | 2004-09-30 | Takeda Pharmaceutical Company Limited | Btc-interacting proteins and use thereof |
| WO2006050475A2 (en) | 2004-11-03 | 2006-05-11 | Brigham And Women's Hospital, Inc. | Identification of dysregulated genes in patients with neurological diseases |
| CA2582270A1 (en) | 2004-11-15 | 2006-05-26 | Blanchette Rockefeller Neurosciences Institute | Abnormalities of phosphatase 2a (pp2a) for diagnosis and treatment of alzheimer's disease |
| WO2007044094A1 (en) | 2005-10-11 | 2007-04-19 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb) |
| US7595167B2 (en) * | 2005-10-11 | 2009-09-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio |
| US20090029873A1 (en) * | 2005-10-11 | 2009-01-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb) |
| EP1934618B1 (de) | 2005-10-11 | 2009-05-13 | Blanchette Rockefeller Neurosciences Institute | Morbus alzheimer-spezifische veränderungen des erk1/erk2-phosphorylierungsverhältnisses - morbus alzheimer-spezifische molekulare biomarker (adsmb) |
| WO2007043998A1 (en) | 2005-10-11 | 2007-04-19 | Blanchette Rockefeller Neurosciences Institute | Alzheimer’s disease-specific alterations of the erk1/erk2 phosphorylation ratio |
| JP2009541863A (ja) | 2006-06-21 | 2009-11-26 | レキシコル メディカル テクノロジー エルエルシー | 痴呆および痴呆型障害を分析および評価するためのシステムおよび方法 |
| KR20140049054A (ko) | 2007-02-09 | 2014-04-24 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | 두부 외상으로 유발된 기억 장애 및 뇌 손상에 대한 브리오스타틴, 브리오로그 및 기타 관련 물질의 치료학적 효과 |
| US20100209914A1 (en) | 2007-05-25 | 2010-08-19 | Ore Pharmaceuticals , Inc. | Methods, systems, and kits for evaluating multiple sclerosis |
-
2002
- 2002-02-27 AT AT02723236T patent/ATE394115T1/de not_active IP Right Cessation
- 2002-02-27 JP JP2002567141A patent/JP4246495B2/ja not_active Expired - Lifetime
- 2002-02-27 DE DE08002964T patent/DE08002964T1/de active Pending
- 2002-02-27 KR KR1020037011307A patent/KR100941597B1/ko not_active Expired - Lifetime
- 2002-02-27 KR KR1020097004352A patent/KR100960256B1/ko not_active Expired - Lifetime
- 2002-02-27 CN CN028078322A patent/CN1549721B/zh not_active Expired - Lifetime
- 2002-02-27 ES ES02723236T patent/ES2305234T3/es not_active Expired - Lifetime
- 2002-02-27 EP EP02723236A patent/EP1385531B1/de not_active Expired - Lifetime
- 2002-02-27 US US10/469,164 patent/US7682807B2/en not_active Expired - Lifetime
- 2002-02-27 DE DE60226429T patent/DE60226429D1/de not_active Expired - Lifetime
- 2002-02-27 ES ES08002964T patent/ES2325350T1/es active Pending
- 2002-02-27 WO PCT/US2002/005672 patent/WO2002067764A2/en not_active Ceased
- 2002-02-27 AU AU2002254029A patent/AU2002254029A1/en not_active Abandoned
-
2008
- 2008-11-07 JP JP2008286869A patent/JP5253971B2/ja not_active Expired - Lifetime
-
2010
- 2010-03-22 US US12/729,042 patent/US9188595B2/en not_active Expired - Lifetime
-
2012
- 2012-12-07 JP JP2012268633A patent/JP2013078330A/ja active Pending
-
2015
- 2015-11-16 US US14/942,758 patent/US20160305961A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20100278803A1 (en) | 2010-11-04 |
| CN1549721B (zh) | 2012-03-07 |
| US9188595B2 (en) | 2015-11-17 |
| KR20090038922A (ko) | 2009-04-21 |
| KR20040086145A (ko) | 2004-10-08 |
| DE08002964T1 (de) | 2009-09-03 |
| US20050059092A1 (en) | 2005-03-17 |
| JP2009148247A (ja) | 2009-07-09 |
| US7682807B2 (en) | 2010-03-23 |
| JP5253971B2 (ja) | 2013-07-31 |
| EP1385531A2 (de) | 2004-02-04 |
| ES2305234T3 (es) | 2008-11-01 |
| US20160305961A1 (en) | 2016-10-20 |
| DE60226429D1 (de) | 2008-06-19 |
| EP1385531A4 (de) | 2004-05-12 |
| WO2002067764A2 (en) | 2002-09-06 |
| CN1549721A (zh) | 2004-11-24 |
| KR100941597B1 (ko) | 2010-02-11 |
| KR100960256B1 (ko) | 2010-06-01 |
| WO2002067764A3 (en) | 2002-11-14 |
| AU2002254029A1 (en) | 2002-09-12 |
| ES2325350T1 (es) | 2009-09-02 |
| JP2004533218A (ja) | 2004-11-04 |
| JP2013078330A (ja) | 2013-05-02 |
| EP1385531B1 (de) | 2008-05-07 |
| JP4246495B2 (ja) | 2009-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60226429D1 (de) | Diagnose der alzheimer-krankheit auf basis von mitogenaktivierter proteinkinase-phosphorylierung | |
| Belew et al. | Evaluation of the white-coat effect in cats | |
| Pepper | Concordance between patients and informants on the personality disorder examination | |
| SE9103332L (sv) | Metod foer diagnos av blodkoagulationssjukdomar | |
| SE9904087D0 (sv) | Recommended replacement time of an implantable medical device | |
| ATE442851T1 (de) | 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a | |
| DE69434152D1 (de) | Vorrichtung zur beurteilungshilfe des kardiovaskulären zustandes eines patienten | |
| BR9808446A (pt) | Processo para diagnosticar doenças psiquiátricas. | |
| Baker et al. | Burnout, sense of coherence and sources of salutogenesis in social workers. | |
| DE69510336D1 (de) | Verfahren zur diagnose von praeklampsie | |
| Kario et al. | The influence of work-and home-related stress on the levels and diurnal variation of ambulatory blood pressure and neurohumoral factors in employed women | |
| James | Blood pressure response to the daily stressors of urban environments: Methodology, basic concepts, and significance | |
| Minniti et al. | Prevalence of hypertension in acromegalic patients: clinical measurement versus 24‐hour ambulatory blood pressure monitoring | |
| DK0764273T3 (da) | Alfa B crystallin til anvendelse i diagnose og terapi af autoimmune sygdomme, især multipel sklerose | |
| PT1895902E (pt) | Monitor de perfusão cerebral | |
| Harshfield et al. | Blood pressure variability and reactivity in the natural environment | |
| DE60023121D1 (de) | Diagnosticher test | |
| EP1925315A3 (de) | Alzheimer-Diagnose auf Basis von mitogenaktivierter Proteinkinasephosphorylierung | |
| RU97115184A (ru) | Способ оценки адаптивных возможностей организма больного | |
| ATE554790T1 (de) | Verfahren und zusammensetzungen zur diagnose von asthma | |
| Picone | Accurate measurement of blood pressure | |
| RU2301016C2 (ru) | Способ оценки индивидуальной социальной защищенности в быту и на производстве | |
| RU2194437C2 (ru) | Способ ранней диагностики гипертонической болезни | |
| RU2001113027A (ru) | Способ диагностики тканевой инсулинорезистентности у различной категории кардиологических больных | |
| ATE220458T1 (de) | Pyridinolin-quervernetzung als hinweis auf krankhafte vorgänge an periodontalen und peripheren implantaten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |